Sequana Medical NV: Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure

PRESS RELEASE MOJAVE study on track to start in Q2 2023 as planned, with initial data by year-end Randomized, controlled study in US seeking to confirm strong efficacy data seen in RED DESERT

Related Keywords

Canada ,United States ,Belgium ,American ,Cian Crosbie ,Nick Bastin ,Jonathan Edwards ,Ethics Committee ,York Heart Association ,Strategic Communications ,Drug Administration ,Company Or Sequanamedical ,Euronext Brussels ,Investigational New Drug ,Chief Medical Officer ,Sequana Medical ,Chief Executive Officer ,Safety Monitoring Board ,New York Heart Association ,Seattle Heart Failure ,North American ,Pre Market Approval ,Sequana ,Medical ,Nnounces ,Clearance ,Application ,Treatment ,Congestive ,Heart ,Failure ,